Pfizer Neurontin Is Second Agent For Postherpetic Neuralgia
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer’s Neurontin is the second drug cleared for treatment of postherpetic neuralgia (PHN), following FDA approval of the new indication May 24.
You may also be interested in...
Pfizer Lyrica Review Notable For Complexity: Four NDAs, Three FDA Divisions
Pfizer’s Lyrica (pregabalin) application may be one of the most exhaustively reviewed NDAs of the user fee era, Lyrica’s complex regulatory history suggests.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product